Neuropathix, Inc. is a biopharmaceutical company. The company is headquartered in Doylestown, Pennsylvania and currently employs 6 full-time employees. The company went IPO on 2016-09-12. The company is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivatives platform potentially useful for a range of inflammatory and neuropathic pain-related diseases. The firm's product candidate includes KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with Chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development, and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its Drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), Chronic Traumatic Encephalopathy (CTE) and CIPN with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.